CeriBell Grows Revenue 36% to $89M, Expands EEG Platform into Pediatrics and Delirium
CFO said CeriBell ended 2025 with $89M revenue, 36% growth and 88% margin, penetrating 3% of a $2B acute-care EEG market across 647 hospitals. Pediatric EEG launch in Q2 and FDA clearance for delirium expanded total addressable market to $3.5B, while breakthrough stroke detection designation paves way for new algorithms.
1. Financial Performance
CFO Scott Blumberg reported CeriBell ended 2025 with $89 million in revenue, a 36% year-over-year increase, and maintained an 88% gross margin. The company’s business model includes subscription fees—accounting for about 25% of revenue at roughly 97% margin—and disposable headbands representing the remaining 75%.
2. Market Penetration and Platform Expansion
CeriBell’s point-of-care EEG platform is installed in 647 of an estimated 6,000 US hospitals with ICU or emergency departments, reflecting approximately 3% market penetration. Upcoming pediatric and neonatal algorithm launches in Q2, alongside a specialized infant head cap, target a $400 million expansion, while delirium clearance increases the total addressable market to about $3.5 billion.
3. Growth Horizons and Regulatory Milestones
The company plans to layer new diagnostic algorithms beyond seizure detection, including delirium and stroke applications. CeriBell received FDA clearance for delirium in November 2025 and a breakthrough designation for stroke detection in January 2026, while pursuing reimbursement pathways and expanding territory coverage with FedRAMP clearance in the VA system.